Mark G Thompson1, Allison Naleway2, Alicia M Fry3, Sarah Ball4, Sarah M Spencer3, Sue Reynolds3, Sam Bozeman2, Min Levine3, Jacqueline M Katz3, Manjusha Gaglani5. 1. Epidemiology and Prevention Branch, Influenza Division/NCIRD/CDC, Atlanta, GA 30333. Electronic address: isq8@cdc.gov. 2. The Center for Health Research, Kaiser Permanente Northwest, Portland, OR 97227. 3. Epidemiology and Prevention Branch, Influenza Division/NCIRD/CDC, Atlanta, GA 30333. 4. Abt Associates, Cambridge, MA 02138. 5. Division of Pediatric Infectious Diseases, Baylor Scott & White Health, Texas A&M HSC COM, Temple, TX 76508.
Abstract
BACKGROUND: Recently, lower estimates of influenza vaccine effectiveness (VE) against A(H3N2) virus illness among those vaccinated during the previous season or multiple seasons have been reported; however, it is unclear whether these effects are due to differences in immunogenicity. METHODS: We performed hemagglutination inhibition antibody (HI) assays on serum collected at preseason, ∼ 30 days post-vaccination, and postseason from a prospective cohort of healthcare personnel (HCP). Eligible participants had medical and vaccination records for at least four years (since July, 2006), including 578 HCP who received 2010-11 trivalent inactivated influenza vaccine [IIV3, containing A/Perth/16/2009-like A(H3N2)] and 209 HCP who declined vaccination. Estimates of the percentage with high titers (≥ 40 and>100) and geometric mean fold change ratios (GMRs) to A/Perth/16/2009-like virus by number of prior vaccinations were adjusted for age, sex, race, education, household size, hospital care responsibilities, and study site. RESULTS: Post-vaccination GMRs were inversely associated with the number of prior vaccinations, increasing from 2.3 among those with 4 prior vaccinations to 6.2 among HCP with zero prior vaccinations (F[4,567]=9.97, p<.0005). Thirty-two percent of HCP with 1 prior vaccination achieved titers >100 compared to only 11% of HCP with 4 prior vaccinations (adjusted odds ratio=6.8, 95% CI=3.1 - 15.3). CONCLUSION: Our findings point to an exposure-response association between repeated IIV3 vaccination and HI for A(H3N2) and are consistent with recent VE observations. Ultimately, better vaccines and vaccine strategies may be needed in order to optimize immunogenicity and VE for HCP and other repeated vaccinees. Published by Elsevier Ltd.
BACKGROUND: Recently, lower estimates of influenza vaccine effectiveness (VE) against A(H3N2) virus illness among those vaccinated during the previous season or multiple seasons have been reported; however, it is unclear whether these effects are due to differences in immunogenicity. METHODS: We performed hemagglutination inhibition antibody (HI) assays on serum collected at preseason, ∼ 30 days post-vaccination, and postseason from a prospective cohort of healthcare personnel (HCP). Eligible participants had medical and vaccination records for at least four years (since July, 2006), including 578 HCP who received 2010-11 trivalent inactivated influenza vaccine [IIV3, containing A/Perth/16/2009-like A(H3N2)] and 209 HCP who declined vaccination. Estimates of the percentage with high titers (≥ 40 and>100) and geometric mean fold change ratios (GMRs) to A/Perth/16/2009-like virus by number of prior vaccinations were adjusted for age, sex, race, education, household size, hospital care responsibilities, and study site. RESULTS: Post-vaccination GMRs were inversely associated with the number of prior vaccinations, increasing from 2.3 among those with 4 prior vaccinations to 6.2 among HCP with zero prior vaccinations (F[4,567]=9.97, p<.0005). Thirty-two percent of HCP with 1 prior vaccination achieved titers >100 compared to only 11% of HCP with 4 prior vaccinations (adjusted odds ratio=6.8, 95% CI=3.1 - 15.3). CONCLUSION: Our findings point to an exposure-response association between repeated IIV3 vaccination and HI for A(H3N2) and are consistent with recent VE observations. Ultimately, better vaccines and vaccine strategies may be needed in order to optimize immunogenicity and VE for HCP and other repeated vaccinees. Published by Elsevier Ltd.
Authors: Joon Young Song; Hee Jin Cheong; In Sook Hwang; Won Suk Choi; Yu Mi Jo; Dae Won Park; Geum Joo Cho; Taik Gun Hwang; Woo Joo Kim Journal: Vaccine Date: 2010-04-13 Impact factor: 3.641
Authors: Mark G Thompson; De-Kun Li; Pat Shifflett; Leslie Z Sokolow; Jeannette R Ferber; Samantha Kurosky; Sam Bozeman; Sue B Reynolds; Roxana Odouli; Michelle L Henninger; Tia L Kauffman; Lyndsay A Avalos; Sarah Ball; Jennifer L Williams; Stephanie A Irving; David K Shay; Allison L Naleway Journal: Clin Infect Dis Date: 2013-11-26 Impact factor: 9.079
Authors: Justin Lessler; Steven Riley; Jonathan M Read; Shuying Wang; Huachen Zhu; Gavin J D Smith; Yi Guan; Chao Qiang Jiang; Derek A T Cummings Journal: PLoS Pathog Date: 2012-07-19 Impact factor: 6.823
Authors: Sanae Sasaki; Xiao-Song He; Tyson H Holmes; Cornelia L Dekker; George W Kemble; Ann M Arvin; Harry B Greenberg Journal: PLoS One Date: 2008-08-20 Impact factor: 3.240
Authors: Puja Van Epps; Terrence Tumpey; Melissa B Pearce; Hana Golding; Patricia Higgins; Thomas Hornick; Christopher Burant; Brigid M Wilson; Richard Banks; Stefan Gravenstein; David H Canaday Journal: Clin Vaccine Immunol Date: 2017-03-06
Authors: Danuta M Skowronski; Catharine Chambers; Gaston De Serres; Suzana Sabaiduc; Anne-Luise Winter; James A Dickinson; Jonathan B Gubbay; Kevin Fonseca; Steven J Drews; Hugues Charest; Christine Martineau; Mel Krajden; Martin Petric; Nathalie Bastien; Yan Li; Derek J Smith Journal: J Infect Dis Date: 2017-04-01 Impact factor: 5.226
Authors: Marieke L A de Hoog; Roderick P Venekamp; Roger A M J Damoiseaux; Anne G M Schilder; Elisabeth A M Sanders; Henriette A Smit; Patricia C J L Bruijning-Verhagen Journal: Ann Fam Med Date: 2019-01 Impact factor: 5.166
Authors: Eunha Shim; Kenneth J Smith; Mary Patricia Nowalk; Jonathan M Raviotta; Shawn T Brown; Jay DePasse; Richard K Zimmerman Journal: Vaccine Date: 2018-01-09 Impact factor: 3.641
Authors: Marc Rondy; Nathalie El Omeiri; Mark G Thompson; Alain Levêque; Alain Moren; Sheena G Sullivan Journal: J Infect Date: 2017-09-18 Impact factor: 6.072